ERBB2 and breast carcinoma: This latter aspect is particularly important for triple-negative (TN) or human epidermal growth factor receptor 2 (HER2)-positive breast cancer, since patients who do not achieve a pathological complete response (pCR) following NACT have a dismal prognosis [2,3].